Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...

Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics). Ahead of the Clinical Trials at the Summit (CTS) meeting in Las ...

Clinical-stage biotechnology company PYC Therapeutics recently held a type B meeting with the US Food and Drug Administration (FDA) to discuss requirements for a new drug application (NDA) for the ...

One of my favorite components of my career has been building a leading clinical trial program at our practice. Clinical science has allowed me to offer cutting-edge treatments in my community while ...

The Dextenza insert provides an additional measure of safety should patients be nonadherent to instructions for postoperative drops. We have all seen patients at a postoperative appointment without ...

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic ...

In a recent study, the researchers suggested that targeting the circuits responsible for visual acuity may be necessary in achieving optimal recovery of visual function and could aid in the ...

In a comprehensive study of geographic atrophy (GA) treatment, Deepak Sambhara, MD, from the Eye Clinic of Wisconsin analyzed long-term patient compliance with two recently FDA-approved complement ...

The Retina World Congress 2025, led by President Barry Kuppermann, represents a pivotal moment in ophthalmological innovation, bringing together international retina specialists to discuss ...

David S. Boyer, MD, discusses a new approach to treating diabetic retinopathy and macular degeneration using suprachoroidal space injections. This innovative technique offers significant advantages ...

An Indonesian study of the characteristics of the retinal vasculature found that the retinal vessel tortuosity (VT) was significantly higher and the fractal dimension (FD) was significantly lower in ...

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.